AIL Dixon Technologies Private Limited, a Joint Venture Company of Dixon Technologies (India) Limited has entered into Memorandum of Understanding (MOU) with Molbio for manufacturing of Truelab™ Quattro Real Time Quantitative micro PCR Analyzer machines. These portable machines are capable of performing 40-48 tests per day of critical infectious diseases.
These technologically driven machines will be manufactured at AIL Dixon's manufacturing facility situated at Tirupati, Andhra Pradesh, India.
Commenting on this occasion, Mr. Atul B. Lall, Managing Director, Dixon Technologies (India) Ltd. said, "We are delighted to associate with Molbio whose Truenat™ Beta CoV machines have been recently validated and approved by Indian Council of Medical Research (ICMR) to conduct Covid-19 tests. Molbio's TrueNat machine is already a breakthrough technology which is capable of diagnosing Tuberculosis and more than 30 other infectious diseases including malaria, chickengunya, dengue, H1N1 etc., in less than an hour's time as well as testing for resistance to drug rifampicin and these machines have been endorsed by World Health Organization (WHO). Molbio's testing/ diagnosis machines are highly advanced and are known for their accuracy in results. We look forward to a prolific association with Molbio who are known for their fully indigenous, revolutionary and disruptive technologies in medical world."
Shares of Dixon Technologies (India) Ltd was last trading in BSE at Rs.5400.05 as compared to the previous close of Rs. 5199.45. The total number of shares traded during the day was 6344 in over 2062 trades.
The stock hit an intraday high of Rs. 5572.75 and intraday low of 5207. The net turnover during the day was Rs. 34275843.